By: Zachary Roberts, M.D., Ph.D

INTRODUCTION

CAR T cell therapy has revolutionized cancer care by harnessing the patient’s immune system to deliver highly personalized and often durable responses in hematologic malignancies once deemed incurable. Despite these outcomes, the widespread adoption of autologous CAR T therapies remains constrained by well-documented barriers – including referral patterns, infrastructure requirements, adverse event management, and manufacturing complexity – underscoring the need for a more accessible, scalable approach.

Next-generation allogeneic, also known as off-the-shelf, CAR T products aim to transform CAR T from a bespoke procedure limited to a small number of academic centers into a scalable therapy that can be offered in community cancer settings, where most patients receive care. With scalable manufacturing, on-demand availability via next-day shipping, and a generally well-tolerated safety profile, off-the-shelf CAR T expands where and how these therapies can be delivered – and when they can be used. This creates the potential to treat patients earlier in the disease course, before the cancer returns and becomes more difficult to treat, and in care settings closer to where they live.

Between 2017 and 2021, three autologous CAR T therapies have been approved for relapsed/refractory large B-cell lymphoma (LBCL). However, fewer than 15% of eligible patients receive treatment¹ due to a complex manufacturing process and the challenging referral pathway to one of the limited number of centers qualified to deliver treatment.

This shift in timing is particularly meaningful as CAR T therapy has historically been reserved for later lines of treatment. However, a growing body of evidence supports its use earlier in the disease course and, ideally, when the disease burden is lower. Findings from studies of cemacabtagene ansegedleucel (cemacel), an investigational off-the-shelf anti-CD19 CAR T product for LBCL, are consistent with observations across other CAR T therapies: patients with lower disease burden tend to respond better to treatment than those with more advanced disease.²

CHANGING THE CURRENT WATCH-AND-WAIT STANDARD OF CARE

The hypothesis that earlier intervention can improve outcomes is currently being tested in the ALPHA3 clinical trial (Allogene Therapeutics). ALPHA3 is the first pivotal, randomized trial to study the use of a CAR T as first-line consolidation in patients with LBCL who have evidence of remaining disease in the form of minimal residual disease (MRD). The trial will assess whether MRD-guided intervention with a one-time dose of cema-cel before clinical relapse can potentially prevent recurrence.

MRD status post 1L treatment has emerged as a strong predictor of relapse in LBCL, creating an opportunity to intervene earlier in the course of disease, when disease burden is low, but risk of progression is high.^3,4 Patients with LBCL who have completed curative-intent treatment in both front-line and later-line settings, including autologous CAR T therapy, and who achieve MRD-negative status have demonstrated improved progression-free survival (PFS) and event-free survival (EFS) compared with those who do not⁵ (Figure 1).

The ALPHA3 trial challenges the standard of care – observation – by introducing a more proactive approach: identifying high-risk patients using Natera’s CLARITY™ MRD assay and treating them before clinical relapse.

The study leverages cema-cel as a one-time, off-the-shelf treatment that can be administered immediately upon discovery of MRD following six cycles of RCHOP or other chemoimmunotherapy regimen, positioning it as the “7th cycle” of frontline treatment for eligible LBCL patients who remain MRD positive.

In April 2026, data from a planned interim futility analysis showed early evidence for the potential of cema-cel in 1L consolidation with MRD clearance of 58.3% in the cema-cel arm versus 16.7% in the observation arm as of the data cutoff – a 41.6 percentage-point absolute difference. Earlier studies have found that as little as a 24% differential in treatment arms led to statistically longer event free survival (EFS).⁶ T ogether, these data highlight the potential for a one-time dose of cema-cel to prevent relapse and improve cure rates (Figure 2).⁷

Importantly in this analysis, cema-cel was well-tolerated as of the data cutoff with no treatment-related serious adverse events. There were no cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GvHD), and there were no treatment-related hospitalizations (Figure 3). This profile compares favorably with the broader CAR T experience, where hospitalization for toxicity management remains common.

BROADENING ACCESS TO COMMUNITY CANCER CENTERS

CAR T therapy has largely been confined to specialized centers, even as most patients are treated in the community setting. Off-the-shelf CAR T potentially changes that by enabling on-demand use and removing key logistical barriers to access.

At the time of the interim analysis, community cancer centers accounted for approximately one-third of screening activity and cema-cel infusions, including sites with limited or even no prior CAR T experience. This shift is further supported by the feasibility of outpatient administration: in the interim futility analysis, 10 of 12 patients treated with cema-cel were managed entirely outpatient post-infusion. This contrasts sharply with the broader CAR T experience, where hospitalization remains common: approximately 70-90% of patients require admission, and about 75% are hospitalized for adverse events within 30 days.⁸

CAR T ON DEMAND

Allogeneic CAR T cells are derived from healthy donors which means that these products are available on demand, allowing patients to begin treatment faster. This also transforms how CAR T therapies are made, using a more advanced, scalable process that allows them to be produced in larger quantities, more like traditional medicines.

At Allogene’s 136,000 square-foot manufacturing facility in Newark, California, the company is able to manufacture upwards of 60,000 doses per year (depending on the product and dose), which is nearly three times more than all CAR T infusions provided to all U.S. cancer patients between 2017 and 2024.⁹ In fact, a single manufacturing run has the potential to yield treatment for more than 100 patients, compared to one patient with an autologous CAR T.

THE FUTURE OF CAR T

CAR T is on the cusp of a fundamental evolution – from a highly personalized, resource-intensive therapy to a scalable, off-the-shelf platform with the potential to deliver curative outcomes in blood cancer. As MRD becomes an established standard for guiding treatment decisions, it creates a powerful opportunity to intervene earlier – treating patients at highest risk of relapse before clinical progression.

A single, well-tolerated infusion of cema-cel as part of first line treatment has the potential to shift blood cancer care from reactive to preventative. Allogeneic CAR T is poised to become the new foundation of cell therapy – enabling earlier MRD-guided intervention, expanding access, and redefining how these therapies are delivered at scale.

REFERENCES

1. Shadman F et al. CAR T cell therapy referral patterns and characteristics of patients with relapsed or refractory (R/R) large B cell lymphoma (LBCL) in the United States. Blood 2025; 146 (Supplement 1): 6272. doi: https://doi.org/10.1182/blood-2025-6272.
2. Locke FL et al. Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies. J Clin Oncol. 2025 May 10;43(14):1695-1705. doi: 10.1200/JCO-24-01933. Epub 2025 Feb 13. PMID: 39946666; PMCID: PMC12058369.
3. Kurtz, et.al. Circulating Tumor DNA Measurements as Early Outcome Predictors in Diffuse Large B-Cell Lymphoma, JCO 2018
4. Alig, et.al., Short Diagnosis-to-Treatment Interval Is Associated with Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma, JCO 2021
5. Roschewski M, Kurtz D M, Westin J R, et al: Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. J Clin Oncol 10.1200/JCO-25-01534
6. Stepan L et al. Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy. J Clin Oncol 0, JCO-2503051. DOI:10.1200/JCO-25-03051
7. Allogene. ALPHA3 Interim Futility Analysis Data Cut. LINK (https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-interim-futility-analysis-pivotal)
8. Majhail NS, Cox T, Larson S, et al. Outpatient administration of chimeric antigen receptor T-cell therapy using remote patient monitoring. JCO Oncology Practice. 2025;21(11):1601-1608. doi:10.1200/OP-25-00062
9. Figures from Center for International Blood & Marrow Transplant Reseach as published in Industry Research: CAR-T Cell Therapy Market Size, Share, Growth, and Industry Analysis, By Type (CD 19,CD 20,GD2,CD22,CD30,CD33,HER1,HER2,Meso,EGFRvlll), By Application (Acute Lymphocytic, Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasta, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular Carcinoma, Colorectal Cancer), Regional Insights and Forecast to 2035.